Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.49 |
| ▸ | ATR | Q13535 | 14/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846265 | 0.81 | CYP4F2 (0.37) | CYP4F2CYP4A11EGFR | |
| SCHEMBL1814227 | 0.75 | AR (0.51) | CYP4F2CYP4A11ATR | |
| SCHEMBL27084373 | 0.75 | CYP4F2 (0.41) | CYP4F2CYP4A11EGFR | |
| SCHEMBL25378381 | 0.74 | CYP4F2 (0.48) | CYP4F2CYP4A11ATREGFR | |
| SCHEMBL1816307 | 0.74 | MAPT (0.49) | CYP4F2CYP4A11ATR | |
| SCHEMBL1816728 | 0.74 | ATR (0.45) | CYP4F2CYP4A11ATR | |
| SCHEMBL25297377 | 0.74 | CYP4F2 (0.47) | CYP4F2CYP4A11ATR | |
| SCHEMBL29176662 | 0.73 | CYP4F2 (0.51) | CYP4F2CYP4A11ATR | |
| SCHEMBL28459866 | 0.73 | CYP4F2 (0.43) | CYP4F2CYP4A11ATR | |
| SCHEMBL1814103 | 0.72 | ATR (0.45) | CYP4F2CYP4A11ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946250-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-03 | — | — | US | disclosed |
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-01-02 | — | — | US | disclosed |
| US-8541575-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| EP-2324008-B1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-05-09 | — | — | EP | disclosed |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-16 | — | — | US | disclosed |
| EP-2324008-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010010154-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | CYP4F2 1337/4885CYP4A11 1503/4885ATR 1023/4885 |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | CYP4F2 1337/4885CYP4A11 1503/4885ATR 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.